Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

P

Parsons TD, Tucker KA, Hall CD, et al. "Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection." AIDS. 2006;20(12):1591-5.
Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, Eron JJ. "Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies." Clin. Infect. Dis.. 2009;49(3):473-6.
Paul RH, Ernst T, Brickman AM, et al. "Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV." J Int Neuropsychol Soc. 2008;14(5):725-33.
Paul RH, Yiannoutsos CT, Miller EN, et al. "Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity." J Neuropsychiatry Clin Neurosci. 2007;19(3):283-92.
Pei L, Hughes MD. "A statistical framework for quantile equivalence clinical trials with application to pharmacokinetic studies that bridge from HIV-infected adults to children." Biometrics. 2008;64(4):1117-25.
Pence BWells, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. "The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2008;47(2):194-201.
Pence BWells, Reif S, Whetten K, et al. "Minorities, the poor, and survivors of abuse: HIV-infected patients in the US deep South." South. Med. J.. 2007;100(11):1114-22.
Périssé ARS, Smeaton L, Chen Y, et al. "Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease." PLoS ONE. 2013;8(12):e83643.
Peters MG, Andersen J, Lynch P, et al. "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127." Hepatology. 2006;44(5):1110-6.
Petersen T, Lee Y-J, Osinusi A, et al. "Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin." AIDS Res. Hum. Retroviruses. 2016;32(7):660-7.
Pillai SK, Pond SLKosakovs, Liu Y, et al. "Genetic attributes of cerebrospinal fluid-derived HIV-1 env." Brain. 2006;129(Pt 7):1872-83.
Podany AT, Bao Y, Swindells S, et al. "Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention." Clin. Infect. Dis.. 2015;61(8):1322-7.
Podany AT, Scarsi KK, Fletcher CV. "Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors." Clin Pharmacokinet. 2017;56(1):25-40.
Pond SLKosakovs, Frost SDW, Grossman Z, Gravenor MB, Richman DD, Brown AJLeigh. "Adaptation to different human populations by HIV-1 revealed by codon-based analyses." PLoS Comput. Biol.. 2006;2(6):e62.
Porter KA, Cole SR, Eron JJ, et al. "HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study." Antimicrob. Agents Chemother.. 2012;56(2):995-1000.
Price P, James I. "IL1A alleles associate with a virological response to antiretroviral therapy in HIV patients beginning therapy with advanced disease." AIDS. 2009;23(9):1173-6.
Putcharoen O, Lee SHee, Henrich TJ, et al. "HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug." J. Virol.. 2012;86(2):1119-28.

R

Raboud JM, Diong C, Carr A, et al. "A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy." HIV Clin Trials. 2010;11(1):39-50.
Ranade K, Geese WJ, Noor M, et al. "Genetic analysis implicates resistin in HIV lipodystrophy." AIDS. 2008;22(13):1561-8.
Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. "Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis." J. Acquir. Immune Defic. Syndr.. 2007;46(4):402-9.
Reynolds NR, Testa MA, Su M, et al. "Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial." J. Acquir. Immune Defic. Syndr.. 2008;47(1):62-8.
Reynolds NR, Neidig JL, Wu AW, Gifford AL, Holmes WC. "Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution." AIDS Care. 2006;18(7):663-73.
Rhee S-Y, Kantor R, Katzenstein DA, et al. "HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes." AIDS. 2006;20(5):643-51.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
Ribaudo HJ, Liu H, Schwab M, et al. "Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study." J. Infect. Dis.. 2010;202(5):717-22.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Ribaudo HJ, Daar ES, Tierney C, et al. "Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202." J. Infect. Dis.. 2013;207(3):420-5.
Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. "Design issues in initial HIV-treatment trials: focus on ACTG A5095." Antivir. Ther. (Lond.). 2006;11(6):751-60.
Ribaudo HJ, Smith KY, Robbins GK, et al. "Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis." Clin. Infect. Dis.. 2013;57(11):1607-17.

Pages